Christopher Ogden - 20 Dec 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Finance and Accounting
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Issuer symbol
CTMX
Transactions as of
20 Dec 2023
Net transactions value
-$2,747
Form type
4
Filing time
22 Dec 2023, 16:10:48 UTC
Previous filing
19 Dec 2023
Next filing
19 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Sale $2,747 -1,990 -3.9% $1.38 48,657 20 Dec 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023.
F2 Includes 30,466 restricted stock units.